Profusa, Inc. Receives Nasdaq Compliance Determination
Profusa confirms Nasdaq bid price and equity rule compliance but remains under a one-year mandatory monitoring period with stricter delisting triggers.
Rhea-AI Summary
Profusa (PFSA) received a Nasdaq Compliance Determination Letter dated September 9, 2026, confirming that the company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) on minimum bid price and Listing Rule 5550(b)(1) on stockholders’ equity.
The company remains subject to a one-year Mandatory Panel Monitor period, during which its compliance with the equity rule will continue to be observed. If during this monitoring period Profusa fails to satisfy the equity rule, Nasdaq will issue a delist determination without offering the opportunity to submit a new compliance plan. Profusa would be able to appeal such a determination by requesting a hearing, which would stay any further Nasdaq action at least until the hearing is held and any extension granted by the Panel expires. The company states that it intends to continue monitoring compliance with all applicable Nasdaq continued listing requirements.
Positive
- Nasdaq compliance restored with Bid Price Rule 5550(a)(2) as of September 9, 2026
- Nasdaq compliance restored with Equity Rule 5550(b)(1), supporting continued listing eligibility
Negative
- Subject to one-year Mandatory Panel Monitor period by Nasdaq
- Equity rule breach during monitoring triggers immediate delist determination without new compliance plan
- Any delist determination would require formal hearing request to stay Nasdaq action
Details
Market reaction after Nasdaq compliance determination: PFSA -9.65%
Following this news, PFSA has declined 9.65%, reflecting a notable negative market reaction. Argus tracked a peak move of +12.8% during the session. Our momentum scanner has triggered 27 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.34. Trading volume is exceptionally heavy at 133.7x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Mandatory Panel Monitor
- 1 year
- Post-compliance monitoring period
Historical Context
-
Nasdaq closed review after confirming compliance with publicly held shares requirement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mandatory panel monitor regulatory
delist determination regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).
The Company remains subject to a one-year Mandatory Panel Monitor (the “Monitoring Period”). If during the Monitoring Period the Company fails to satisfy the equity rule, the company will not be provided the opportunity to submit a compliance plan; rather, Nasdaq will issue a delist determination, which the company may appeal by requesting a hearing. Such request would stay any further action by Nasdaq at least until the hearing is held and any extension granted by the Panel expires.
The Company intends to continue to monitor its compliance with all applicable Nasdaq continued listing requirements.
About Profusa, Inc.
Based in Berkeley, California, Profusa is a digital health company pioneering next-generation biosensor technologies, previously announced the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3 Vision Labs, Inc. and its subsidiaries (“G3"). Upon option exercising, the combined company is expected to operate as a public diagnostics company.
Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s ability to maintain compliance with Nasdaq listing standards, the Company’s plans to monitor its continued compliance, and the potential consequences of non-compliance during the Mandatory Panel Monitor period. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Investor and Media Contacts:
email: info@coreir.com
phone: 1(212) 655-0924
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq rules has Profusa demonstrated compliance with?
Profusa has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2), known as the Bid Price Rule, and Nasdaq Listing Rule 5550(b)(1), known as the Equity Rule, as confirmed in the Compliance Determination Letter dated September 9, 2026.
What is the Mandatory Panel Monitor period mentioned by Profusa?
The company remains subject to a one-year Mandatory Panel Monitor, referred to as the Monitoring Period, during which Nasdaq will continue to monitor Profusa’s compliance with the equity rule.
What happens if Profusa fails the equity rule during the Monitoring Period?
If during the Monitoring Period Profusa fails to satisfy the equity rule, Nasdaq will issue a delist determination and will not provide an opportunity to submit a new compliance plan. Profusa may appeal by requesting a hearing, which would stay further Nasdaq action at least until the hearing is held and any extension granted by the Panel expires.
How does Profusa plan to address ongoing Nasdaq listing requirements?
The company states that it intends to continue to monitor its compliance with all applicable Nasdaq continued listing requirements.